CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report)’s share price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.24 and traded as high as $0.24. CytoDyn shares last traded at $0.21, with a volume of 2,048,823 shares.
CytoDyn Stock Performance
The stock’s fifty day simple moving average is $0.24 and its two-hundred day simple moving average is $0.17. The company has a market capitalization of $260.04 million, a price-to-earnings ratio of -21.10 and a beta of 1.33.
About CytoDyn
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
- Five stocks we like better than CytoDyn
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Disney 2025 Shareholders: Major Updates for Investors
- What Does Downgrade Mean in Investing?
- Advance Auto Parts Stock: A Classic Rebound Play in the Making
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
